AIMTC Inc Ordinary Shares TCAI 深 沪
等待开盘 08-19 09:30:00 美东时间
25.3646
+0.080
+0.31%
华盛通- 最 高25.39
- 今 开25.38
- 成交量 7069股
- 最 低 25.245
- 昨 收 25.2851
- 总市值 355.10万
- 52周最高 25.87
- 市盈率 静 --
- 换手率 5.05%
- 52周最低 24.95
- 委 比 33.33%
- 总股本 14.00万
- 历史最高 25.87
- 量 比 0.32
- 振 幅 0.57%
- 历史最低 24.95
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
<p>AIM ImmunoTech reported positive progress in its pancreatic cancer pipeline programs, highlighting promising Phase 2 trial results for Ampligen® in combination with Imfinzi®. The company also bolstered its cash position with an $8 million equity offering, funding operations for approximately 12 months. Key updates included resumed trading on NYSE American, a mid-year clinical data update, and upcoming scientific presentations. Financial highli...
08-15 13:00
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
<p>Live video webcast on Wednesday, August 20th at 2:40 PM ET</p> <p>OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), today announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, held virtually August 19-21, 2025. The presentation will be on Wednesday, August 20, 2025 at 2:40 PM ET, presented by Thomas Equels, CEO, President & Executive Vice Chairman. Registra...
08-14 12:55
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
AIM ImmunoTech Inc. announced that its drug Ampligen will present updates on its progress in late-stage pancreatic cancer, multiple solid tumor types, and its mechanism of action in oncology at the 5th Annual Marie Sklodowska-Curie Symposium in Warsaw, Poland, September 3-5, 2025. The presentations will include recent data from the DURIPANC study, showing promising survival outcomes and safety profiles, as well as Ampligen’s potential as a thera...
08-06 13:00
New ETF Digs Into Pipes, Power And Plugs Behind The AI Revolution
The Tortoise AI Infrastructure ETF is a unique way to invest in the infrastructure that powers the AI revolution. It focuses on energy, data centers, and technology infrastructure. Tortoise's expertise in this sector and its risk-disciplined approach make this ETF stand out. Launch date: August 4. Price at listing: ~$25.27. Expense ratio: 0.65%.
08-06 03:08
